# Ferring Pharmaceuticals

Rebyota (RBX2660) — First-in-world approved microbiota liquid enema.

Source: https://en.bioecon.ru/companies/ferring-pharmaceuticals/
Updated: 2026-07-01

- Country: Switzerland

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | €121 million payment related to the Rebyota approval and settlement agreement with previous shareholders of Rebiotix Inc (acquired in 2018) | https://www.ferring.com/wp-content/uploads/sites/16/2023/03/Ferring-Pharmaceuticals-Annual-Report-2022.pdf |
| Production site | dedicated U.S. manufacturing facility; Rebiotix, Inc. facility in Roseville, MN; and dedicated gene therapy drug product facility at Parsippany, New Jersey | https://ferringusa.com/?press=ferring-highlights-commitment-to-c-diff-infection-community-on-the-second-anniversary-of-the-launch-of-rebyota-fecal-microbiota-live-jslm, https://ferringusa.com/wp-content/uploads/sites/12/2022/12/9009000002_REBYOTA-PI_11-2022.pdf |
| Regulatory approval | FDA approved in 2022; Health Canada authorized on March 5, 2025 | https://www.businesswire.com/news/home/20251029308256/en/Ferring-Pharmaceuticals-to-Explore-Strategic-Options-for-Rebyota, https://www.ferring.ca/media/1385/rebyota-pm-control-no-285129-en-mar-5-2025.pdf, https://www.ferring.com/ferring-receives-u-s-fda-approval-for-rebyota-fecal-microbiota-live-jslm-a-novel-first-in-class-microbiota-based-live-biotherapeutic/, https://www.ferring.com/wp-content/uploads/sites/16/2025/04/Ferring-Pharmaceuticals-Annual-Report-2024.pdf, https://www.ferring.com/wp-content/uploads/sites/16/2026/02/Ferring-Pharmaceuticals-Annual-Report-2023.pdf |
| Headcount | More than 7,000 people (global, as of 2024); more than 7,500 (global, as of 2025); more than 900 (U.S., as of 2025) | https://www.businesswire.com/news/home/20251029308256/en/Ferring-Pharmaceuticals-to-Explore-Strategic-Options-for-Rebyota, https://www.ferring.com/ferring-receives-u-s-fda-approval-for-rebyota-fecal-microbiota-live-jslm-a-novel-first-in-class-microbiota-based-live-biotherapeutic/, https://www.ferring.com/wp-content/uploads/sites/16/2025/04/Ferring-Pharmaceuticals-Annual-Report-2024.pdf |
| Revenue | Total global revenues of €2,343 million (2024); over €2.5 billion (2025) | https://www.businesswire.com/news/home/20251029308256/en/Ferring-Pharmaceuticals-to-Explore-Strategic-Options-for-Rebyota, https://www.ferring.com/wp-content/uploads/sites/16/2025/04/Ferring-Pharmaceuticals-Annual-Report-2024.pdf |

Independent sources: businesswire.com, ferringusa.com

## Technologies

- [Microbiome therapeutics (live biotherapeutic products)](https://en.bioecon.ru/technology/microbiome-therapeutics-lbps/)